Skip to main content

Table 2 Initial empiric antibiotic therapy in modified intention-to-treat patients grouped as defined per bacteriologic documentation (visit 2)

From: Empiric broad-spectrum antibiotic therapy of nosocomial pneumonia in the intensive care unit: a prospective observational study

  Group I (n = 113, 46.3%) Group II (n = 14, 5.7%) Group III (n = 38, 15.6%) Group IV (n = 56, 23.0%) Group V (n = 23, 9.4%) Overall (n = 244, 100%) Chi-square P value
Dose of imipenem (%)        0.51
   <3 g/day 19.5 - 10.5 9.0 17.3 14.3  
   3 g/day 62.8 85.7 73.7 60.7 65.2 65.6  
   >3 g/day 17.7 14.3 15.8 30.4 17.4 20.1  
Empiric regimen (%)        0.64
   Imipenem only 19.5 7.1 18.4 21.4 8.7 18.0  
   Imipenem + aminoglycoside 37.2 50.0 42.2 48.2 34.8 41.0  
Amikacin 24.8 28.6 21.1 41.1 26.1 28.3  
Tobramycin 12.4 21.4 21.1 7.1 8.7 12.7  
   Imipenem + glycopeptide 15.0 21.4 21.1 8.9 21.7 15.6  
Vancomycin 9.7 21.4 13.2 8.9 13.0 11.1  
Teicoplanin 5.3 - 7.9 - 8.7 4.5  
   Imipenem + aminoglycoside + glycopeptide 28.3 21.4 18.4 21.4 34.8 25.4  
  1. Group I, patients with an unknown aetiology and unmodified therapy; Group II, patients with resistant organisms, who had unmodified therapy; Group III, patients with susceptible organisms, who had unmodified therapy; Group IV, patients who had susceptible organisms and whose therapy was modified accordingly; and, Group V, patients who initially received inadequate antibiotic therapy, which was later modified on the basis of cultures.